Clinical Trial Update: Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women [Phase 3]

View source ↗

Summary

Phase 3 long-term safety results for elagolix in combination with estradiol/norethindrone acetate for heavy menstrual bleeding associated with uterine fibroids …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heavy Menstrual Bleeding
• Uterine Fibroids

Drugs mentioned

• ESTRADIOL / NORETHINDRONE ACETATE (Estradiol and norethindrone acetate)
• Elagolix (elagolix)

Snippet

Sponsor: AbbVie | Conditions: Heavy Menstrual Bleeding, Uterine Fibroids | Phase 3 | Status: COMPLETED | Results posted: 2025-07-22